Certified by Founder Lodge
ReCode Therapeutics
United States - Menlo Park, California & Dallas, Texas
START UP
1 Disclosed Funding Rounds $50,000,000
0 Participating Investments
-
Founded date
2015
-
Operating Status
Active
-
Last Funding Type
Seed
-
Company Type
For Profit
- Website
- Contact
- Social Links
ReCode Therapeutics is a clinical-stage genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics. ReCode’s selective organ targeting (
| Date | Round | Raised | Participating Investors |
|---|---|---|---|
| September, 20 ,2023 | Series B | $50,000,000 |
OrbiMed
Amgen
Pfizer
Osage University Partners (OUP)
Solasta Ventures
Vida Ventures, LLC
Matrix Capital Management Company, L.P.
Leaps by Bayer
MPM BioImpact
Bioluminescence Ventures
EcoR1 Capital, LLC
Carmot Therapeutics, Inc.
Ozette Technologies
NAPIGEN, INC.
TrueBinding
Loopworm
Transaera, Inc. | $10,500,000 | (Nov 5, 2024)
Algebrik AI | $4,000,000 | (Nov 5, 2024)
Insider. | $500,000,000 | (Nov 5, 2024)
Cintoo | $40,246,701 | (Nov 5, 2024)
Advex AI | $3,500,000 | (Nov 5, 2024)
